



## **ONCOlog Medical receives an 11 million SEK PatLog® order for Prague**

*Uppsala, Sweden, July 29, 2009 Press release*

ONCOlog Medical has received an order through its partner IBA (Ion Beam Applications S.A.) of a PatLog system for the Proton Radiotherapy Centre in Prague, Czech Republic.

This Proton Center will have four treatment rooms equipped with the PatLog® systems for out-of-treatment room set up.

The choice of PatLog® is a result of the successful cooperation between IBA and ONCOlog Medical which has resulted in the first ongoing installation of a full PatLog® system in Essen, Germany.

“This order is a strategic market proof of our novel PatLog® concept for better and more cost efficient radiotherapy, and will have big importance for our company’s success on the global radiotherapy market”, says Hans Dahlin, CEO of ONCOlog Medical.

The novel PatLog® approach of out-of- treatment room set up and smooth transportation of the patient between different imaging devices and treatment rooms, will highly improve the patient throughput in large radiotherapy clinics, at the same time as the treatment Accuracy, patient Comfort and clinical Efficiency will be better.

“Due to the increasing demand for proton radiotherapy, especially for treatment of children, and the need for more cost efficiency in cancer care, we foresee many new PatLog® orders to come in the near future, through our integrated partnership with IBA, as well as through our own sales resources”, continues Hans Dahlin.

### **About ONCOlog Medical**

ONCOlog Medical is dedicated to innovative solutions in Radiation Therapy. The company mission is to bring Better Radiotherapy to More People by improved Accuracy, Comfort and Efficiency in Cancer care. The company was founded in 2002 and is owned by SLS Invest AB, LinkMed (LMED), Management and staff.

Website: [www.oncologmedical.com](http://www.oncologmedical.com)

### **About IBA**

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### **For further information please contact:**

Hans Dahlin, CEO, [hans.dahlin@oncologmedical.com](mailto:hans.dahlin@oncologmedical.com), +46 18 19 45 63

Stefan Mejerwall, Technical Manager, [stefan.mejerwall@oncologmedical.com](mailto:stefan.mejerwall@oncologmedical.com), +46 18 19 45 66